Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/ijms20010083
Keywords
osteoporosis; anabolic therapy; bone regeneration; parathyroid hormone; sclerostin; romosozumab; denosumab
Funding
- German Research Foundation (DFG) [KE 2179/2-1, TS 303/2-1]
- Else-Kroner-Fresenius Stiftung [EKFS 2017_A22]
- Berlin Institute of Health
- German Research Foundation (DFG)
- Open Access Publication Fund of Charite-Universitatsmedizin Berlin
Ask authors/readers for more resources
Osteoporosis represents the most common bone disease worldwide and results in a significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the development of osteoporosis are also associated with delayed fracture healing and impaired bone regeneration. Based on a steadily increasing life expectancy in modern societies, the global implications of osteoporosis and impaired bone healing are substantial. Research in the last decades has revealed several molecular pathways that stimulate bone formation and could be targeted to treat both osteoporosis and impaired fracture healing. The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available